KR20240002123A - Oral disintegrating formulation containing rhubarb root extract and manufacturing method thereof - Google Patents
Oral disintegrating formulation containing rhubarb root extract and manufacturing method thereof Download PDFInfo
- Publication number
- KR20240002123A KR20240002123A KR1020220131344A KR20220131344A KR20240002123A KR 20240002123 A KR20240002123 A KR 20240002123A KR 1020220131344 A KR1020220131344 A KR 1020220131344A KR 20220131344 A KR20220131344 A KR 20220131344A KR 20240002123 A KR20240002123 A KR 20240002123A
- Authority
- KR
- South Korea
- Prior art keywords
- orally disintegrating
- orally
- tablets
- paragraph
- disintegrant
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 21
- 239000000284 extract Substances 0.000 title claims abstract description 20
- 235000009411 Rheum rhabarbarum Nutrition 0.000 title claims abstract description 13
- 241000219061 Rheum Species 0.000 title claims abstract 6
- 239000000203 mixture Substances 0.000 title claims description 33
- 238000009472 formulation Methods 0.000 title claims description 21
- 238000002360 preparation method Methods 0.000 claims abstract description 56
- 239000007884 disintegrant Substances 0.000 claims description 46
- 239000003826 tablet Substances 0.000 claims description 29
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 18
- 239000003795 chemical substances by application Substances 0.000 claims description 15
- 238000002156 mixing Methods 0.000 claims description 12
- 239000006191 orally-disintegrating tablet Substances 0.000 claims description 12
- 239000000843 powder Substances 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 8
- 229930195725 Mannitol Natural products 0.000 claims description 8
- 239000007919 dispersible tablet Substances 0.000 claims description 8
- 239000000594 mannitol Substances 0.000 claims description 8
- 235000010355 mannitol Nutrition 0.000 claims description 8
- 239000000725 suspension Substances 0.000 claims description 8
- 235000003599 food sweetener Nutrition 0.000 claims description 7
- 239000008187 granular material Substances 0.000 claims description 7
- 239000003765 sweetening agent Substances 0.000 claims description 7
- 229920002261 Corn starch Polymers 0.000 claims description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 6
- 229930006000 Sucrose Natural products 0.000 claims description 6
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 6
- 239000008120 corn starch Substances 0.000 claims description 6
- 239000002245 particle Substances 0.000 claims description 6
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 6
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 6
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 6
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 5
- 235000010443 alginic acid Nutrition 0.000 claims description 5
- 229920000615 alginic acid Polymers 0.000 claims description 5
- 239000000783 alginic acid Substances 0.000 claims description 5
- 229960001126 alginic acid Drugs 0.000 claims description 5
- 150000004781 alginic acids Chemical class 0.000 claims description 5
- -1 alkali metal salts Chemical class 0.000 claims description 5
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 5
- 239000000499 gel Substances 0.000 claims description 5
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 5
- 239000005720 sucrose Substances 0.000 claims description 5
- 239000000811 xylitol Substances 0.000 claims description 5
- 235000010447 xylitol Nutrition 0.000 claims description 5
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 5
- 229960002675 xylitol Drugs 0.000 claims description 5
- 244000215068 Acacia senegal Species 0.000 claims description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 4
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 4
- 229920000084 Gum arabic Polymers 0.000 claims description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 4
- 235000010489 acacia gum Nutrition 0.000 claims description 4
- 239000000205 acacia gum Substances 0.000 claims description 4
- 239000000654 additive Substances 0.000 claims description 4
- 239000007910 chewable tablet Substances 0.000 claims description 4
- 229920001577 copolymer Polymers 0.000 claims description 4
- 239000008103 glucose Substances 0.000 claims description 4
- 229920001277 pectin Polymers 0.000 claims description 4
- 235000010987 pectin Nutrition 0.000 claims description 4
- 239000001814 pectin Substances 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 239000000600 sorbitol Substances 0.000 claims description 4
- 235000010356 sorbitol Nutrition 0.000 claims description 4
- 239000003381 stabilizer Substances 0.000 claims description 4
- 239000006190 sub-lingual tablet Substances 0.000 claims description 4
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 3
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 3
- 229930091371 Fructose Natural products 0.000 claims description 3
- 239000005715 Fructose Substances 0.000 claims description 3
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 3
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 3
- 229910052783 alkali metal Inorganic materials 0.000 claims description 3
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 3
- 239000007938 effervescent tablet Substances 0.000 claims description 3
- 239000010408 film Substances 0.000 claims description 3
- 239000001341 hydroxy propyl starch Substances 0.000 claims description 3
- 235000013828 hydroxypropyl starch Nutrition 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 239000004094 surface-active agent Substances 0.000 claims description 3
- 239000006188 syrup Substances 0.000 claims description 3
- 235000020357 syrup Nutrition 0.000 claims description 3
- OMDQUFIYNPYJFM-XKDAHURESA-N (2r,3r,4s,5r,6s)-2-(hydroxymethyl)-6-[[(2r,3s,4r,5s,6r)-4,5,6-trihydroxy-3-[(2s,3s,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]methoxy]oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@H](O)[C@H](O)O1 OMDQUFIYNPYJFM-XKDAHURESA-N 0.000 claims description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 claims description 2
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 claims description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 2
- 229920000945 Amylopectin Polymers 0.000 claims description 2
- 229920000856 Amylose Polymers 0.000 claims description 2
- 241000416162 Astragalus gummifer Species 0.000 claims description 2
- 229920002101 Chitin Polymers 0.000 claims description 2
- 229920001661 Chitosan Polymers 0.000 claims description 2
- 239000001856 Ethyl cellulose Substances 0.000 claims description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 2
- 229920000926 Galactomannan Polymers 0.000 claims description 2
- 108010010803 Gelatin Proteins 0.000 claims description 2
- 229920002907 Guar gum Polymers 0.000 claims description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
- 239000005913 Maltodextrin Substances 0.000 claims description 2
- 229920002774 Maltodextrin Polymers 0.000 claims description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 2
- 229920001615 Tragacanth Polymers 0.000 claims description 2
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 claims description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 claims description 2
- 239000003963 antioxidant agent Substances 0.000 claims description 2
- 125000003118 aryl group Chemical group 0.000 claims description 2
- 239000000440 bentonite Substances 0.000 claims description 2
- 229910000278 bentonite Inorganic materials 0.000 claims description 2
- 235000012216 bentonite Nutrition 0.000 claims description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 claims description 2
- 239000006189 buccal tablet Substances 0.000 claims description 2
- 235000010418 carrageenan Nutrition 0.000 claims description 2
- 229920001525 carrageenan Polymers 0.000 claims description 2
- 239000000679 carrageenan Substances 0.000 claims description 2
- 229940113118 carrageenan Drugs 0.000 claims description 2
- 239000005018 casein Substances 0.000 claims description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims description 2
- 235000021240 caseins Nutrition 0.000 claims description 2
- 235000010980 cellulose Nutrition 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 claims description 2
- 239000001913 cellulose Substances 0.000 claims description 2
- 239000003086 colorant Substances 0.000 claims description 2
- 239000008121 dextrose Substances 0.000 claims description 2
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 2
- 229920001249 ethyl cellulose Polymers 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- 235000001727 glucose Nutrition 0.000 claims description 2
- 235000010417 guar gum Nutrition 0.000 claims description 2
- 239000000665 guar gum Substances 0.000 claims description 2
- 229960002154 guar gum Drugs 0.000 claims description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 2
- 238000001802 infusion Methods 0.000 claims description 2
- 239000003456 ion exchange resin Substances 0.000 claims description 2
- 229920003303 ion-exchange polymer Polymers 0.000 claims description 2
- 239000000905 isomalt Substances 0.000 claims description 2
- 235000010439 isomalt Nutrition 0.000 claims description 2
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- 235000015122 lemonade Nutrition 0.000 claims description 2
- 235000010449 maltitol Nutrition 0.000 claims description 2
- 239000000845 maltitol Substances 0.000 claims description 2
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 claims description 2
- 229940035436 maltitol Drugs 0.000 claims description 2
- 229940035034 maltodextrin Drugs 0.000 claims description 2
- 229920000609 methyl cellulose Polymers 0.000 claims description 2
- 235000010981 methylcellulose Nutrition 0.000 claims description 2
- 239000001923 methylcellulose Substances 0.000 claims description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 2
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 2
- 230000003232 mucoadhesive effect Effects 0.000 claims description 2
- 229920000642 polymer Polymers 0.000 claims description 2
- 229920001451 polypropylene glycol Polymers 0.000 claims description 2
- 229920002689 polyvinyl acetate Polymers 0.000 claims description 2
- 239000011118 polyvinyl acetate Substances 0.000 claims description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 2
- 235000010413 sodium alginate Nutrition 0.000 claims description 2
- 239000000661 sodium alginate Substances 0.000 claims description 2
- 229940005550 sodium alginate Drugs 0.000 claims description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 2
- 235000019830 sodium polyphosphate Nutrition 0.000 claims description 2
- 235000010487 tragacanth Nutrition 0.000 claims description 2
- 239000000196 tragacanth Substances 0.000 claims description 2
- 229940116362 tragacanth Drugs 0.000 claims description 2
- 229920001285 xanthan gum Polymers 0.000 claims description 2
- 235000010493 xanthan gum Nutrition 0.000 claims description 2
- 239000000230 xanthan gum Substances 0.000 claims description 2
- 229940082509 xanthan gum Drugs 0.000 claims description 2
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims description 2
- 229920002307 Dextran Polymers 0.000 claims 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 1
- 229920002845 Poly(methacrylic acid) Polymers 0.000 claims 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims 1
- 229910052751 metal Inorganic materials 0.000 claims 1
- 239000002184 metal Substances 0.000 claims 1
- 239000011574 phosphorus Substances 0.000 claims 1
- 229910052698 phosphorus Inorganic materials 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 17
- 230000000704 physical effect Effects 0.000 abstract description 7
- 230000000052 comparative effect Effects 0.000 description 15
- 244000299790 Rheum rhabarbarum Species 0.000 description 7
- 150000005846 sugar alcohols Chemical class 0.000 description 7
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 210000000214 mouth Anatomy 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 5
- 150000001720 carbohydrates Chemical class 0.000 description 5
- 238000004090 dissolution Methods 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 235000013376 functional food Nutrition 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 238000005469 granulation Methods 0.000 description 4
- 230000003179 granulation Effects 0.000 description 4
- 235000016623 Fragaria vesca Nutrition 0.000 description 3
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 3
- 240000001972 Gardenia jasminoides Species 0.000 description 3
- 244000228451 Stevia rebaudiana Species 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 239000001055 blue pigment Substances 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000000691 measurement method Methods 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 3
- 238000001694 spray drying Methods 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- 108010011485 Aspartame Proteins 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- 244000307700 Fragaria vesca Species 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- 239000004368 Modified starch Substances 0.000 description 2
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 239000004376 Sucralose Substances 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 239000000605 aspartame Substances 0.000 description 2
- 235000010357 aspartame Nutrition 0.000 description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 2
- 229960003438 aspartame Drugs 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229940105329 carboxymethylcellulose Drugs 0.000 description 2
- 150000002016 disaccharides Chemical class 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000001630 malic acid Substances 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- 235000019426 modified starch Nutrition 0.000 description 2
- 150000002772 monosaccharides Chemical class 0.000 description 2
- 235000021096 natural sweeteners Nutrition 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 150000004804 polysaccharides Chemical class 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 235000019408 sucralose Nutrition 0.000 description 2
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 2
- 230000009747 swallowing Effects 0.000 description 2
- 235000013616 tea Nutrition 0.000 description 2
- 239000000892 thaumatin Substances 0.000 description 2
- 235000010436 thaumatin Nutrition 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- 244000099147 Ananas comosus Species 0.000 description 1
- 235000007119 Ananas comosus Nutrition 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 description 1
- 244000024873 Mentha crispa Species 0.000 description 1
- 235000014749 Mentha crispa Nutrition 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 229920001100 Polydextrose Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 230000001164 bioregulatory effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229940068682 chewable tablet Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 238000007542 hardness measurement Methods 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 239000008123 high-intensity sweetener Substances 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 235000013615 non-nutritive sweetener Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 235000013856 polydextrose Nutrition 0.000 description 1
- 239000001259 polydextrose Substances 0.000 description 1
- 229940035035 polydextrose Drugs 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229940098466 sublingual tablet Drugs 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229940074410 trehalose Drugs 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Molecular Biology (AREA)
- Botany (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Physiology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Nutrition Science (AREA)
- Medicinal Preparation (AREA)
Abstract
구강 붕해 제제 및 이의 제조 방법에 관한 것으로, 일 양상에 따른 루바브뿌리추출물 및 구강붕해제를 포함하는 구강 붕해 제제에 의하면, 구강 내 붕해성이 우수하고 구강 붕해 제제에 적합한 물성을 갖는 효과가 있다.Pertaining to an orally disintegrating preparation and a method for manufacturing the same, the orally disintegrating preparation comprising a rhubarb root extract and an orally disintegrating agent according to one aspect has excellent oral disintegration properties and has physical properties suitable for an orally disintegrating preparation. .
Description
본 발명은 구강 붕해 제제 및 이의 제조 방법에 관한 것이다. The present invention relates to orally disintegrating preparations and methods for their preparation.
일반적으로 정제나 캅셀제는 물과 함께 삼켜서 복용해야 하나 이러한 복용법이 불편하거나 실행 불가능할 수 있다. 특히, 노인, 유아, 어린이, 연하운동이 곤란한 사람, 수분 섭취를 제한해야 하는 환자, 치매나 파킨슨병 등 신체적, 정신적인 이유에서 관리가 어려운 환자와 같은 경우 통상적인 방법으로 정제를 투여하기 곤란하다. Generally, tablets or capsules should be taken by swallowing them with water, but this method may be inconvenient or impractical. In particular, it is difficult to administer tablets in the usual way for the elderly, infants, children, people with difficulty swallowing, patients who need to limit water intake, and patients who are difficult to manage due to physical or mental reasons such as dementia or Parkinson's disease. .
이러한 불편함을 개선하기 위하여 개발된 것이 구강 붕해 제제이다. 최근에는 다양한 방법으로 구강 붕해 제제를 제조하는 기술이 각광을 받고 있다. 구강 붕해 제제는 물 없이 구강에서 타액에 의하여 신속히 붕해 및 용해됨으로써 용액 혹은 현탁액 상태로 되어 타액 등과 함께 순차적으로 구강, 식도, 십이지장, 소장 등 소화기 관의 흡수부위로 이동한다. 이러한 제제는 물 없이 복용을 가능하게 하여 복용이 용이할 뿐만 아니라, 유효성분이 신속하게 흡수될 수 있는 특성을 가지고 있다.Orally disintegrating preparations were developed to improve this inconvenience. Recently, technologies for manufacturing orally disintegrating preparations using various methods have been in the spotlight. Orally disintegrating preparations are rapidly disintegrated and dissolved by saliva in the oral cavity without water, forming a solution or suspension, and sequentially move to the absorption sites of the digestive tract, such as the oral cavity, esophagus, duodenum, and small intestine, along with saliva. These preparations are not only easy to take by allowing them to be taken without water, but also have the characteristic of allowing the active ingredients to be absorbed quickly.
현재까지 다양한 구강 붕해 제제의 제조공정이 개발되어 있는데, 널리 사용되고 있는 것 중 하나는 분무건조(spray dry)법이다. 분무건조법을 이용한 가장 대표적인 방법은 일본 야마노치(Yamanouchi) 제약사의 와우탭(WowTab) 기술이다. 상기 방법은 저성형성 당류와 고성형성 당류를 적당한 비율로 혼합한 후, 약물과 함께 분무건조하여 제조한 정제이다.To date, various manufacturing processes for orally disintegrating preparations have been developed, and one of the widely used methods is spray drying. The most representative method using spray drying is the WowTab technology from Yamanouchi Pharmaceutical Company of Japan. In this method, tablets are manufactured by mixing low-formability saccharides and high-formability saccharides in an appropriate ratio and then spray-drying them with the drug.
이러한 구강 붕해 제제의 주(主)부형제로 당, 당알코올 등이 사용되고 있다. 그러나, 당 또는 당알코올은 타정성이 좋지 않아 이를 주부형제로 사용하는 경우 결정 셀룰로오스와 같은 기능성 부형제를 혼합하거나 활택제의 양을 증가하는 등의 방법으로 타정성을 높이고자 하고 있다. 그러나 이러한 경우, 구강 붕해 제제를 투여하였을 때 식감이 나쁘고 이물감이 느껴지며 붕해시간이 길어지는 문제점이 있다. 따라서, 보다 붕해성이 우수한 구강 붕해 제제의 제조방법의 개발이 필요한 실정이다.Sugar, sugar alcohol, etc. are used as main excipients in these orally disintegrating preparations. However, sugar or sugar alcohol has poor tabletting properties, so when using it as a main excipient, attempts are made to improve tableting properties by mixing functional excipients such as crystalline cellulose or increasing the amount of lubricant. However, in this case, when the orally disintegrating agent is administered, there are problems such as poor texture, foreign body sensation, and long disintegration time. Therefore, there is a need to develop a method for manufacturing an orally disintegrating preparation with superior disintegrability.
일 양상은 루바브뿌리추출물 및 구강붕해제를 포함하는 구강 붕해 제제를 제공하는 것이다.One aspect is to provide an orally disintegrating formulation comprising a rhubarb root extract and an orally disintegrating agent.
다른 양상은 i) 부형제 및 붕해제를 혼합하고 과립화하여 구강붕해제를 제조하는 단계;Another aspect includes the steps of i) mixing excipients and disintegrants and granulating to prepare an orally disintegrant;
ii) 상기 구강붕해제 및 루바브뿌리추출물을 혼합하는 단계; 및ii) mixing the orally disintegrant and rhubarb root extract; and
iii) 상기 혼합물을 제제화 하는 단계를 포함하는 루바브뿌리추출물 및 구강붕해제를 포함하는 구강 붕해 제제의 제조 방법을 제공하는 것이다.iii) to provide a method for producing an orally disintegrating formulation containing a rubab root extract and an orally disintegrating agent, including the step of formulating the mixture.
일 양상은 루바브뿌리추출물 및 구강붕해제를 포함하는 구강 붕해 제제를 제공한다.One aspect provides an orally disintegrating formulation comprising a rhubarb root extract and an orally disintegrating agent.
상기 구강붕해제는 구강 붕해 제제의 제조에 사용되는 붕해성을 갖는 혼합물을 의미한다.The orally disintegrant refers to a mixture having disintegration properties used in the production of orally disintegrating preparations.
일 구체예에 있어서, 상기 구강붕해제는 과립화된 것일 수 있다.In one embodiment, the orally disintegrant may be granulated.
상기 과립화는 구강붕해제의 유동성 및 타정성을 증진시키는 공정이라면, 그 공정의 종류는 특별히 제한되지 않으며, 예를 들면, 건식법, 습식법 또는 유동층 조립법 등에 의해 과립화가 수행될 수 있다. 이중 결합액을 사용하는 제조공정은 습식법, 유동층 조립법이 있으며 결합액 없이 결합제만 사용하는 제조공정은 건식법이 있다.As long as the granulation is a process that improves the fluidity and tabletability of the orally disintegrant, the type of process is not particularly limited, and for example, the granulation may be performed by a dry method, a wet method, or a fluidized bed granulation method. Manufacturing processes using a double binder include a wet method and a fluidized bed assembly method, and manufacturing processes using only a binder without a binder include a dry method.
일 구체예에 있어서, 상기 구강붕해제는 구강 붕해 제제 총 중량을 기준으로 1 내지 95 중량%, 1 내지 94 중량%, 1 내지 93 중량%, 1 내지 92 중량%, 1 내지 91 중량%, 1 내지 90 중량%, 1 내지 89 중량%, 10 내지 95 중량%, 20 내지 95 중량%, 30 내지 95 중량%, 40 내지 95 중량%, 50 내지 95 중량%, 60 내지 95 중량%, 70 내지 95 중량%, 80 내지 95 중량%, 10 내지 94 중량%, 20 내지 93 중량%, 30 내지 92 중량%, 40 내지 91 중량%, 50 내지 90 중량%, 60 내지 89 중량%, 70 내지 89 중량% 또는 80 내지 89 중량%로 포함될 수 있다.In one embodiment, the orally disintegrating agent is present in an amount of 1 to 95% by weight, 1 to 94% by weight, 1 to 93% by weight, 1 to 92% by weight, 1 to 91% by weight, 1 based on the total weight of the orally disintegrating agent. to 90% by weight, 1 to 89% by weight, 10 to 95% by weight, 20 to 95% by weight, 30 to 95% by weight, 40 to 95% by weight, 50 to 95% by weight, 60 to 95% by weight, 70 to 95% by weight Weight %, 80 to 95 weight %, 10 to 94 weight %, 20 to 93 weight %, 30 to 92 weight %, 40 to 91 weight %, 50 to 90 weight %, 60 to 89 weight %, 70 to 89 weight % Alternatively, it may be included at 80 to 89% by weight.
상기 구강붕해제는 부형제 및 붕해제를 포함할 수 있다.The orally disintegrant may include excipients and disintegrants.
일 구체예에 있어서, 상기 부형제는 만니톨, 솔비톨, 자일리톨, 이소말트, 글루코스, 말토덱스트린, 트레할로스, 덱스트로스, 수크로스, 프럭토스, 말토스, 말티톨, 메틸셀룰로오스, 미결정 셀룰로오즈, 유당, 저치환도 히드록시셀룰로오스, 카르복시메칠셀룰로오스 또는 카르복시메칠셀룰오스의 알칼리 금속염, 카라기난, 갈락토만난, 트라가칸트, 펙틴, 키토산 또는 키틴의 유도체, 아라비아고무, 잔탄검, 알긴산 또는 알간산 알칼리 금속, 폴리메타크릴산 또는 그의 염, 메타크릴레이트 공중합체, 폴리비닐알코올, 폴리비닐피롤리돈, 폴리비닐피롤리돈과 비닐아세테이트의 공중합체, 폴리프로필렌옥사이드 및 그의 중합체로 이루어진 군으로부터 선택된 1종 이상인 것일 수 있다.In one embodiment, the excipients include mannitol, sorbitol, xylitol, isomalt, glucose, maltodextrin, trehalose, dextrose, sucrose, fructose, maltose, maltitol, methylcellulose, microcrystalline cellulose, lactose, low degree of substitution. Hydroxycellulose, carboxymethylcellulose or alkali metal salts of carboxymethylcellulose, carrageenan, galactomannan, tragacanth, pectin, chitosan or derivatives of chitin, gum arabic, xanthan gum, alginic acid or alkali metal alganate, polymethacrylic It may be one or more types selected from the group consisting of acids or salts thereof, methacrylate copolymers, polyvinyl alcohol, polyvinylpyrrolidone, copolymers of polyvinylpyrrolidone and vinyl acetate, polypropylene oxide, and polymers thereof. .
일 구체예에 있어서 상기 부형제는 만니톨 일 수 있다. 부형제의 평균 입자 크기에는 특별한 제한이 없지만, 바람직하게는 10 내지 200 μm, 더욱 바람직하게는 10 내지 100 μm, 더욱 더 바람직하게는 10 내지 50 μm 이다. 바람직한 입자 크기를 달성하기 위해, 필요에 따라서 적합하게는 분쇄 제품을 사용한다.In one embodiment, the excipient may be mannitol. The average particle size of the excipient is not particularly limited, but is preferably 10 to 200 μm, more preferably 10 to 100 μm, and even more preferably 10 to 50 μm. To achieve the desired particle size, ground products are suitably used as needed.
상기 부형제는 붕해성, 용해성, 성형성, 타정성(tabletability), 안정성 등을 개선하려는 목적으로 구강 붕해 제제 총 중량을 기준으로 1 내지 80 중량%, 1 내지 79 중량%, 1 내지 78 중량%, 1 내지 77 중량%, 1 내지 76 중량%, 1 내지 75 중량%, 10 내지 80 중량%, 20 내지 80 중량%, 30 내지 80 중량%, 40 내지 80 중량%, 50 내지 80 중량%, 10 내지 79 중량%, 20 내지 78 중량%, 30 내지 77 중량%, 40 내지 76 중량% 또는 50 내지 75 중량%로 포함될 수 있다.The excipients are used in an amount of 1 to 80% by weight, 1 to 79% by weight, 1 to 78% by weight, based on the total weight of the orally disintegrating preparation for the purpose of improving disintegration, solubility, moldability, tabletability, stability, etc. 1 to 77% by weight, 1 to 76% by weight, 1 to 75% by weight, 10 to 80% by weight, 20 to 80% by weight, 30 to 80% by weight, 40 to 80% by weight, 50 to 80% by weight, 10 to 80% by weight It may be included at 79% by weight, 20 to 78% by weight, 30 to 77% by weight, 40 to 76% by weight, or 50 to 75% by weight.
일 구체예에 있어서, 상기 붕해제는 옥수수전분, 히드록시프로필메칠셀룰로오스, 벤토나이트, 히드록시프로필스타치, 카르복시메칠셀룰로오스나트륨, 알긴산나트륨, 라우릴황산나트륨, 무수규산, 1-히드록시프로필셀룰로오스, 덱스트란, 이온교환수지, 초산폴리비닐, 포름알데히드처리 카제인 및 젤라틴, 알긴산, 아밀로오스, 구아르고무(Guar gum), 중조 폴리비닐피롤리돈, 아라비아고무, 아밀로펙틴, 펙틴, 폴리인산나트륨, 에칠셀룰로오스, 백당 및 규산마그네슘알루미늄으로 이루어진 군으로부터 선택된 1종 이상인 것일 수 있다.In one embodiment, the disintegrant is corn starch, hydroxypropyl methylcellulose, bentonite, hydroxypropyl starch, sodium carboxymethyl cellulose, sodium alginate, sodium lauryl sulfate, silicic anhydride, 1-hydroxypropyl cellulose, Dex. Tran, ion exchange resin, polyvinyl acetate, formaldehyde treated casein and gelatin, alginic acid, amylose, guar gum, sodium bicarbonate polyvinylpyrrolidone, gum arabic, amylopectin, pectin, sodium polyphosphate, ethyl cellulose, It may be one or more types selected from the group consisting of white sugar and magnesium aluminum silicate.
일 구체예에 있어서 상기 붕해제는 옥수수전분일 수 있다. 붕해제의 평균 입자 크기에는 특별한 제한이 없지만, 바람직하게는 10 내지 200 μm, 더욱 바람직하게는 10 내지 100 μm, 더욱 더 바람직하게는 10 내지 50 μm 이다. 바람직한 입자 크기를 달성하기 위해, 필요에 따라서 적합하게는 분쇄 제품을 사용한다.In one embodiment, the disintegrant may be corn starch. There is no particular limitation on the average particle size of the disintegrant, but is preferably 10 to 200 μm, more preferably 10 to 100 μm, and even more preferably 10 to 50 μm. To achieve the desired particle size, ground products are suitably used as needed.
상기 붕해제는 단독으로 또는 조합으로 사용할 수 있다.The disintegrants can be used alone or in combination.
상기 붕해제는 구강 붕해 제제 총 중량을 기준으로 1 내지 25 중량%, 1 내지 24 중량%, 1 내지 23 중량%, 1 내지 22 중량%, 1 내지 21 중량%, 1 내지 20 중량%, 5 내지 25 중량%, 10 내지 25 중량%, 15 내지 25 중량%, 5 내지 24 중량%, 10 내지 23 중량%, 15 내지 22 중량%, 15 내지 21 중량% 또는 15 내지 20 중량%로 포함될 수 있다.The disintegrant is used in an amount of 1 to 25% by weight, 1 to 24% by weight, 1 to 23% by weight, 1 to 22% by weight, 1 to 21% by weight, 1 to 20% by weight, 5 to 5%, based on the total weight of the orally disintegrating preparation. It may be included at 25% by weight, 10 to 25% by weight, 15 to 25% by weight, 5 to 24% by weight, 10 to 23% by weight, 15 to 22% by weight, 15 to 21% by weight, or 15 to 20% by weight.
붕해제가 옥수수전분 또는 히드록시프로필전분의 경우, 붕해제는 바람직하게는 4 내지 20 중량%, 더욱 바람직하게는 4 내지 15 중량%, 더욱 더 바람직하게는 8 내지 12 중량%의 비율로 사용할 수 있다.When the disintegrant is corn starch or hydroxypropyl starch, the disintegrant can be used in an amount of preferably 4 to 20% by weight, more preferably 4 to 15% by weight, and even more preferably 8 to 12% by weight. there is.
일 구체예에 있어서, 상기 구강 붕해 제제는 성형, 안정화, 맛의 개량 등을 목적으로 감미료, 산미료, 향료, 색소류, 항산화제, 안정화제, 계면활성제 등과 같은 첨가제를 추가로 포함할 수 있다. 이러한 첨가제는, 구강 붕해 제제의 붕해 시간 또는 경도에 악영향을 주지 않는 정도의 양으로 첨가할 수 있다.In one embodiment, the orally disintegrating preparation may further include additives such as sweeteners, acidulants, flavorings, pigments, antioxidants, stabilizers, surfactants, etc. for the purpose of shaping, stabilizing, improving taste, etc. These additives can be added in an amount that does not adversely affect the disintegration time or hardness of the orally disintegrating preparation.
상기 감미료의 예에는 자일리톨, 에리트리톨, 소르비톨, 트레할로오스, 글루코오스, 수크로오스 등의 당류 및 당 알코올류, 및 아스파탐, 수크랄로오스, 사카린 나트륨, 2칼륨 글리키르리지네이트, 타우마틴, 스테비아 등의 고 감미도 감미료가 포함된다. Examples of the sweeteners include sugars and sugar alcohols such as xylitol, erythritol, sorbitol, trehalose, glucose, and sucrose, and aspartame, sucralose, sodium saccharin, dipotassium glycyrrhizinate, thaumatin, and stevia. Includes high-intensity sweeteners such as
상기 향료의 예에는 딸기, 오렌지, 파인애플, 요구르트, 페퍼민트, 스페어민트, 멘톨 등이 포함된다.Examples of the flavoring include strawberry, orange, pineapple, yogurt, peppermint, spearmint, menthol, etc.
상기 언급된 산미료의 예에는 구연산, 말산, 타르타르산 등이 포함된다.Examples of the above-mentioned acidulants include citric acid, malic acid, tartaric acid, etc.
본 발명에 따른 제제는 경구 투여용으로 제제화될 수 있으며, 예컨대 정제(tablet), 필름제, 현탁제(suspension), 과립제(granule), 겔제(gel), 환제(pill), 틴크제(tincture), 전제(decoction), 침제(infusion), 주정제(spirit), 유동엑스제(fluidextract), 엘릭서제(elixir), 엑스제(extract), 시럽제(syrup), 산제(powder), 방향수제(aromatic water), 레모네이드제(lemonade) 등의 다양한 형태로 제제화될 수 있다. The preparation according to the present invention can be formulated for oral administration, such as tablets, films, suspensions, granules, gels, pills, tinctures. , decoction, infusion, spirit, fluidextract, elixir, extract, syrup, powder, aromatic It can be formulated in various forms such as water, lemonade, etc.
상기 정제(tablet)는 예컨대, 구강붕해정(orally disintegrating tablet), 부착정(mucoadhesive tablet), 분산정(dispersible tablet), 설하정(sublingual tablet), 바칼정(buccal tablet), 저작정(chewable tablet), 비등정(발포정-effervescent tablet), 용해정(solution tablet) 등의 다양한 형태로 제제화될 수 있다. 그리고, 통상의 기술자라면 상기 다양한 정제를 필요에 따라 다양하게 변형하여 사용할 수 있다. 보다 바람직하게, 액상형이나 구강 내에서 용해, 분산 또는 붕해되는 제형(즉, 구강 내 붕해성)일 수 있다. 예컨대 구강내 분산성 제형, 예컨대 구강용해필름, 구강붕해정, 현탁액, 현탁정, 속효성붕해정, 구강붕해과립, 구강붕해트로키제, 설하정, 산제 및/또는 츄어블정과 같은 제형일 수 있다. 이들 제형은 바람직하게 구강 투여 후 10분 또는 5분 이내에 전체 제제의 80% 이상이 용해, 분산 또는 붕해될 수 있다. 상기 구강용해필름(orally dissolving film)은 필름(film), 스트립(strip), 구강붕해필름(orally disintegrating film) 등의 용어와 상호 교환적으로 사용될 수 있으며, 혀 위, 구강점막, 설하 등 구강 내에 붙여 녹여 복용하는 제형을 말한다. 본 발명에 따른 구강붕해필름 및 속효성분해 정제 제형의 구강 투여용 제제는 물 없이 복용 가능하다는 장점이 있다.The tablets include, for example, orally disintegrating tablets, mucoadhesive tablets, dispersible tablets, sublingual tablets, buccal tablets, and chewable tablets. ), effervescent tablets, and solution tablets. In addition, a person skilled in the art can use the above various tablets by modifying them in various ways as needed. More preferably, it may be a liquid form or a dosage form that dissolves, disperses, or disintegrates in the oral cavity (i.e., orally disintegrable). For example, it may be an orally dispersible dosage form, such as an orally dispersible film, an orally disintegrating tablet, a suspension, a suspension tablet, a rapidly disintegrating tablet, an orally disintegrating granule, an orally disintegrating troche, a sublingual tablet, a powder, and/or a chewable tablet. . These formulations preferably allow more than 80% of the total formulation to be dissolved, dispersed, or disintegrated within 10 or 5 minutes after oral administration. The orally dissolving film can be used interchangeably with terms such as film, strip, and orally disintegrating film, and can be used interchangeably in the oral cavity such as on the tongue, oral mucosa, and sublingually. It refers to a dosage form that is taken by sticking it inside the body and dissolving it. The formulation for oral administration in the form of an orally disintegrating film and a fast-acting disintegrating tablet according to the present invention has the advantage of being able to be taken without water.
상기 구강 붕해 제제는 구강용해필름, 구강붕해정, 현탁액, 현탁정, 속효성붕해정, 구강붕해과립, 구강붕해트로키제, 설하정, 산제 및 츄어블정으로 이루어진 군에서 선택된 어느 하나 이상의 제형일 수 있다.The orally disintegrating preparation may be one or more dosage forms selected from the group consisting of orally disintegrating film, orally disintegrating tablets, suspensions, suspension tablets, rapidly disintegrating tablets, orally disintegrating granules, orally disintegrating troches, sublingual tablets, powders, and chewable tablets. You can.
상기 구강 붕해 제제는 통상적으로 구강 붕해 제제에 사용되는 성분을 더 포함할 수 있으며, 통상적으로 약학 제제에 첨가할 수 있는 약학적으로 허용가능한 담체를 더 포함할 수 있다. 상기 약학적으로 허용가능한 담체는 약제학 분야에서 통상적으로 사용되는 부형제, 가소화제, 붕해제, 희석제, 용매, 침투 증진제, 보존제, 완충제, 겔 형성제, 윤활제, 담체, 안정화제, 겔, 염료, 안료, 계면활성제, 불활성 충진제, 점착제, 조직화제(texturizers), 연화제, 유화제 및 이들의 혼합물 등의 첨가제를 포함한다.The orally disintegrating preparation may further include ingredients typically used in orally disintegrating preparations, and may further include a pharmaceutically acceptable carrier that can be typically added to pharmaceutical preparations. The pharmaceutically acceptable carrier includes excipients, plasticizers, disintegrants, diluents, solvents, penetration enhancers, preservatives, buffers, gel formers, lubricants, carriers, stabilizers, gels, dyes, and pigments commonly used in the pharmaceutical field. , surfactants, inert fillers, adhesives, texturizers, softeners, emulsifiers, and mixtures thereof.
일 구체예에 있어서, 상기 구강 붕해 제제는 루바브뿌리추출물을 포함할 수 있다. 상기 루바브뿌리추출물은 구강 붕해 제제 총 중량을 기준으로 0.0001 내지 60 중량%, 예를 들면 0.13334 내지 4 중량%, 0.2 내지 3 중량%, 0.3 내지 1 중량%, 또는 0.4 내지 0.5 중량%로 포함될 수 있다.In one embodiment, the orally disintegrating preparation may include rubab root extract. The rhubarb root extract may be included in an amount of 0.0001 to 60% by weight, for example, 0.13334 to 4% by weight, 0.2 to 3% by weight, 0.3 to 1% by weight, or 0.4 to 0.5% by weight, based on the total weight of the orally disintegrating preparation. there is.
구강 붕해 제제의 붕해시간은 petri dish에 거즈를 깔고 그 위에 구강 붕해 제제를 놓은 다음, 일정 농도의 치자청색소를 포함하는 용액 일정량을 스포이드로 점적하여 정제의 형태가 무너지는 시점까지의 시간을 측정하는 방법으로 얻을 수 있다.The disintegration time of an orally disintegrating preparation is measured by placing gauze on a petri dish, placing the orally disintegrating preparation on it, and then injecting a certain amount of a solution containing a certain concentration of gardenia blue pigment with a dropper to measure the time until the tablet loses its shape. It can be obtained by doing this:
구강 내에서 신속하게 붕해하기 위해 필요한 시간(붕해시간)에는, 사람 마다 다소 차이가 있지만 본 발명에서는 구강 붕해 제제를 구강 내에 넣은 후, 180초 이내, 바람직하게는 90초 이내, 더욱 바람직하게는 60초 이내에 완전히 붕해되는 것을 의미할 수 있다.The time required for rapid disintegration in the oral cavity (disintegration time) varies slightly from person to person, but in the present invention, after placing the orally disintegrating agent in the oral cavity, it is administered within 180 seconds, preferably within 90 seconds, more preferably within 60 seconds. This can mean complete disintegration within seconds.
일 구체예에 있어서, 상기 구강 붕해 제제는 붕해시간이 180초 이내, 90초 이내, 60초 이내일 수 있다.In one embodiment, the orally disintegrating preparation may have a disintegration time of within 180 seconds, within 90 seconds, or within 60 seconds.
구강 붕해 제제의 경도는 경도계(Hardness tester TBH325 TD, Erweka, 독일)를 사용하여 측정할 수 있다.The hardness of orally disintegrating preparations can be measured using a hardness tester TBH325 TD, Erweka, Germany.
일 구체예에 있어서, 상기 구강 붕해 제제는 경도가 1 내지 9kp, 1 내지 8kp, 1 내지 7kp, 1 내지 6kp, 1 내지 5kp, 2 내지 9kp, 3 내지 9kp, 4 내지 9kp, 2 내지 8kp, 3 내지 7kp, 4 내지 6kp 또는 4 내지 5kp일 수 있다.In one embodiment, the orally disintegrating formulation has a hardness of 1 to 9kp, 1 to 8kp, 1 to 7kp, 1 to 6kp, 1 to 5kp, 2 to 9kp, 3 to 9kp, 4 to 9kp, 2 to 8kp, 3. It may be from 7 kp, 4 to 6 kp, or 4 to 5 kp.
구강 붕해 제제의 마손도는 USP 1216의 Tablet friability 챕터에 기재된 정제 마손도 측정방법으로 얻을 수 있다.Friability of orally disintegrating formulations can be obtained by the tablet friability measurement method described in the Tablet friability chapter of USP 1216.
일 구체예에 있어서, 상기 구강 붕해 제제는 마손도가 0.01 내지 0.8%, 0.01 내지 0.7%, 0.01 내지 0.6%, 0.01 내지 0.5%, 0.01 내지 0.4%, 0.1 내지 0.8%, 0.2 내지 0.8%, 0.3 내지 0.8%, 0.2 내지 0.7%, 0.3 내지 0.6%, 0.3 내지 0.5% 또는 0.3 내지 0.4%일 수 있다.In one embodiment, the orally disintegrating formulation has a friability of 0.01 to 0.8%, 0.01 to 0.7%, 0.01 to 0.6%, 0.01 to 0.5%, 0.01 to 0.4%, 0.1 to 0.8%, 0.2 to 0.8%, 0.3. to 0.8%, 0.2 to 0.7%, 0.3 to 0.6%, 0.3 to 0.5%, or 0.3 to 0.4%.
본 발명에 따른 상기 구강 붕해 제제는 건강기능식품에 사용될 수 있다.The orally disintegrating preparation according to the present invention can be used in health functional foods.
본 명세서에서 용어 "건강기능식품"은 건강보조의 목적으로 특정성분을 원료로 하거나 식품 원료에 들어있는 특정성분을 추출, 농축, 정제, 혼합 등의 방법으로 제조, 가공한 식품을 말하며, 상기 성분에 의해 생체방어, 생체리듬의 조절, 질병의 방지와 회복 등 생체조절기능을 생체에 대하여 충분히 발휘할 수 있도록 설계되고 가공된 식품을 말한다. 상기 건강기능식품 조성물은 미세먼지에 의한 피부 손상의 예방 및 개선 등과 관련된 기능을 수행할 수 있다.In this specification, the term "health functional food" refers to a food manufactured or processed using specific ingredients as raw materials or by extracting, concentrating, refining, or mixing specific ingredients contained in food raw materials for the purpose of health supplementation. It refers to food designed and processed to fully exert bioregulatory functions on the living body, such as biodefense, regulation of biorhythm, and prevention and recovery of disease. The health functional food composition can perform functions related to preventing and improving skin damage caused by fine dust.
상기 식품의 종류에는 특별한 제한은 없다. 상기 추출물을 첨가할 수 있는 식품의 예로는 산제, 과립제, 정제, 캡슐제, 환제, 겔, 젤리, 현탁액, 에멀젼, 시럽제, 티백제, 침출차, 껌, 캔디류 및 건강 음료로 이루어진 군으로부터 선택되는 제형 등이 있으며 통상적인 의미에서의 건강식품을 모두 포함한다.There are no special restrictions on the types of foods above. Examples of foods to which the extract can be added include formulations selected from the group consisting of powders, granules, tablets, capsules, pills, gels, jellies, suspensions, emulsions, syrups, tea bags, leached teas, gums, candies, and health drinks. and includes all health foods in the conventional sense.
상기 건강음료 조성물은 통상의 음료와 같이 여러 가지 감미제, 향미제 또는 천연 탄수화물 등을 추가 성분으로서 포함할 수 있다. 상기 감미제는 천연감미제 또는 합성 감미제일 수 있다. 천연감미제는 타우마틴(taumatin) 또는 스테비아(stevia) 추출물일 수 있고, 합성감미제는 사카린(saccharin), 수크랄로스(sucralose) 또는 아스파르탐(aspartame)일 수 있다.The health drink composition may include various sweeteners, flavoring agents, or natural carbohydrates as additional ingredients, like ordinary drinks. The sweetener may be a natural sweetener or a synthetic sweetener. The natural sweetener may be thaumatin or stevia extract, and the synthetic sweetener may be saccharin, sucralose, or aspartame.
상기 천연 탄수화물은 모노사카라이드(monosaccharide), 디사카라이드(disaccharide), 폴리사카라이드(polysaccharide), 자일리톨(xylitol), 소르비톨(sorbitol) 또는 에리트리톨(erythritol)일 수 있다. 상기 모노사카라이드는 포도당 또는 과당일 수 있고, 디사카라이드는 말토오스(maltose) 또는 수크로오스(sucrose)일 수 있다. 폴리사카라이드는 덱스트린(dextrin) 또는 사이클로덱스트린(cyclodextrin)일 수 있다. 상기 천연 탄수화물의 비율은 본 발명의 조성물 100 ml 당 일반적으로 약 0.01 내지 10 g, 예를 들면, 약 0.01 내지 0.1 g일 수 있다.The natural carbohydrate may be monosaccharide, disaccharide, polysaccharide, xylitol, sorbitol, or erythritol. The monosaccharide may be glucose or fructose, and the disaccharide may be maltose or sucrose. The polysaccharide may be a dextrin or cyclodextrin. The proportion of the natural carbohydrate may generally be about 0.01 to 10 g, for example, about 0.01 to 0.1 g per 100 ml of the composition of the present invention.
상기 건강기능식품에는 식품학적으로 허용 가능한 식품 보조 첨가제를 포함할 수 있으며, 건강기능식품의 제조에 통상적으로 사용되는 적절한 담체를 포함할 수 있다.The health functional food may include food supplements that are foodologically acceptable, and may include an appropriate carrier commonly used in the manufacture of health functional foods.
상기 외에 본 발명의 조성물은 여러 가지 영양제, 비타민, 전해질, 풍미제, 착색제, 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알코올, 탄산 음료에 사용되는 탄산화제 등을 포함할 수 있다. 그 밖에 본 발명의 조성물은 천연 과일주스, 과일주스 음료 및 야채 음료의 제조를 위한 과육을 포함할 수 있다. 이러한 성분은 독립적으로 또는 조합하여 사용할 수 있다. 이러한 첨가제의 비율은 크게 중요하진 않지만 본 발명의 조성물 100 중량부 당 0.01 내지 0.1 중량부의 범위에서 선택되는 것이 일반적이다.In addition to the above, the composition of the present invention contains various nutrients, vitamins, electrolytes, flavors, colorants, pectic acid and its salts, alginic acid and its salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohol, It may include carbonating agents used in carbonated drinks. Additionally, the composition of the present invention may include pulp for the production of natural fruit juice, fruit juice beverages, and vegetable beverages. These ingredients can be used independently or in combination. The ratio of these additives is not very important, but is generally selected in the range of 0.01 to 0.1 parts by weight per 100 parts by weight of the composition of the present invention.
다른 양상은 i) 부형제 및 붕해제를 혼합하고 과립화하여 구강붕해제를 제조하는 단계;Another aspect includes i) mixing excipients and disintegrants and granulating to prepare an orally disintegrant;
ii) 상기 구강붕해제 및 루바브뿌리추출물을 혼합하는 단계; 및ii) mixing the orally disintegrant and rhubarb root extract; and
iii) 상기 혼합물을 제제화 하는 단계를 포함하는 루바브뿌리추출물 및 구강붕해제를 포함하는 구강 붕해 제제의 제조 방법을 제공한다.iii) It provides a method for producing an orally disintegrating formulation containing a rubab root extract and an orally disintegrating agent, including the step of formulating the mixture.
일 구체예에 있어서, 상기 과립화는 부형제 및 붕해제를 혼합하고 교반하여 수행될 수 있다.In one embodiment, the granulation may be performed by mixing excipients and disintegrants and stirring.
상기 부형제 및 붕해제는 1 : 0.1 내지 1의 중량비로 혼합될 수 있다.The excipient and disintegrant may be mixed at a weight ratio of 1:0.1 to 1.
상기 교반은 50 내지 90℃, 60 내지 80℃ 또는 70℃에서 수행될 수 있다.The stirring may be performed at 50 to 90°C, 60 to 80°C, or 70°C.
일 양상에 따른 루바브뿌리추출물 및 구강붕해제를 포함하는 구강 붕해 제제에 의하면, 구강 내 붕해성이 우수하고 구강 붕해 제제에 적합한 물성을 갖는 효과가 있다.According to one aspect, an orally disintegrating preparation containing a rhubarb root extract and an orally disintegrating agent has excellent oral disintegration properties and has physical properties suitable for an orally disintegrating preparation.
도 1은 본 발명에 따른 구강붕해제를 제조하는 공정을 나타내는 그림이다.
도 2는 제조예 1, 비교제조예 1 및 비교제조예 3의 수분흡수율을 평가한 결과이다.Figure 1 is a diagram showing the process for manufacturing an orally disintegrant according to the present invention.
Figure 2 shows the results of evaluating the moisture absorption rate of Preparation Example 1, Comparative Preparation Example 1, and Comparative Preparation Example 3.
이하 본 발명을 실시예를 통하여 보다 상세하게 설명한다. 그러나, 이들 실시예는 본 발명을 예시적으로 설명하기 위한 것으로 본 발명의 범위가 이들 실시예에 한정되는 것은 아니다. Hereinafter, the present invention will be described in more detail through examples. However, these examples are for illustrative purposes only and the scope of the present invention is not limited to these examples.
본 발명의 명세서 및 청구범위에 사용된 용어 또는 단어는 통상적이거나 사전적인 의미로 한정 해석되지 아니하며, 발명자는 그 자신의 발명을 가장 최선의 방법으로 설명하기 위해 용어의 개념을 적절하게 정의할 수 있다는 원칙에 입각하여 본 발명의 기술적 사상에 부합하는 의미와 개념으로 해석되어야만 한다.The terms or words used in the specification and claims of the present invention are not to be construed as limited to their ordinary or dictionary meanings, and the inventor may appropriately define the concept of terms to explain his or her invention in the best way. It must be interpreted as meaning and concept consistent with the technical idea of the present invention based on principles.
본 발명의 명세서 전체에 있어서, 어떤 부분이 어떤 구성 요소를 "포함" 한다고 할 때, 이는 특별히 반대되는 기재가 없는 한 다른 구성 요소를 제외하는 것이 아니라 다른 구성 요소를 더 포함할 수 있는 것을 의미한다.Throughout the specification of the present invention, when a part is said to "include" a certain component, this means that it does not exclude other components but may further include other components, unless specifically stated to the contrary. .
본 발명의 명세서 전체에 있어서, "A 및/또는 B"는, A 또는 B, 또는 A 및 B를 의미한다.Throughout the specification of the present invention, “A and/or B” means A or B, or A and B.
실시예 1: 과립화 구강붕해제Example 1: Granulated Orally Disintegrant
만니톨 및 변성전분을 8 : 2의 비율로 혼합하고, 50 Brix농도로 용해시켰다. 70℃에서 60분간 교반하고, 95℃에서 30분간 처리하여 살균하였다. 그 후 평판 열풍 건조하고 분쇄하여 과립을 수득하였다. 수득된 과립을 40메쉬로 체별하였다.Mannitol and modified starch were mixed at a ratio of 8:2 and dissolved to a Brix concentration of 50. It was stirred at 70°C for 60 minutes and sterilized by treatment at 95°C for 30 minutes. Afterwards, the plate was hot-air dried and pulverized to obtain granules. The obtained granules were sieved with 40 mesh.
비교예 1: 단순혼합식 구강붕해제Comparative Example 1: Simple mixed oral disintegrant
만니톨 및 변성전분을 8 : 2의 비율로 혼합하고 40메쉬로 체별하였다.Mannitol and modified starch were mixed at a ratio of 8:2 and sieved through a 40 mesh.
비교예 2: 당알콜베이스의 구강붕해제 1Comparative Example 2: Sugar alcohol-based orally disintegrant 1
만니톨을 구강붕해제로 사용하였다.Mannitol was used as an orally disintegrant.
비교예 3: 당알콜베이스의 구강붕해제 2Comparative Example 3: Sugar alcohol-based orally disintegrant 2
자일리톨 및 폴리덱스트로스를 9.5 : 0.5의 비율로 혼합하고 40메쉬로 체별하였다.Xylitol and polydextrose were mixed at a ratio of 9.5:0.5 and sieved with 40 mesh.
제조예 1Manufacturing Example 1
실시예 1의 구강붕해제를 포함하는 구강붕해정을 제조하였다.An orally dispersible tablet containing the orally disintegrant of Example 1 was prepared.
구체적으로, 하기의 표 1의 배합비로 혼합하고 타정하여 구강붕해정을 제조하였다.Specifically, orally disintegrating tablets were prepared by mixing and compressing at the mixing ratio shown in Table 1 below.
비교제조예 1 내지 3Comparative Manufacturing Examples 1 to 3
비교예 1 내지 3의 구강붕해제를 포함하는 구강붕해정을 제조하였다.Orally dispersible tablets containing the orally disintegrants of Comparative Examples 1 to 3 were prepared.
구강붕해제로 비교예 1 내지 3을 사용한 것을 제외하고는 상기 제조예 1의 조성과 동일하게 제조하였다.The composition was prepared in the same manner as in Preparation Example 1, except that Comparative Examples 1 to 3 were used as orally disintegrants.
실험예 1: 용해시간 평가Experimental Example 1: Dissolution time evaluation
실시예 1 및 비교예 1 내지 3의 구강붕해제를 포함하는 제조예 1 및 비교제조예 1 내지 3의 구강붕해정의 용해시간을 평가하였다. 구체적으로, petri dish에 거즈를 깔고 그 위에 구강붕해정을 놓은 다음, 일정 농도의 치자청색소를 포함하는 용액 일정량을 스포이드로 점적하여 정제의 형태가 무너지는 시점까지의 시간을 측정하였다.The dissolution time of the orally dispersible tablets of Preparation Example 1 and Comparative Preparation Examples 1 to 3 containing the orally disintegrants of Example 1 and Comparative Examples 1 to 3 was evaluated. Specifically, a gauze was laid on a petri dish and an orally disintegrating tablet was placed on it. Then, a certain amount of a solution containing a certain concentration of gardenia blue pigment was instilled with a dropper, and the time until the tablet lost its shape was measured.
실험예 2: 물성 평가Experimental Example 2: Physical property evaluation
제조예 1 및 비교제조예 1 내지 3의 물성을 평가하였다. 구체적으로 300g 분량을 타정한 뒤 임의로 샘플링하여 물성을 평가하였다.The physical properties of Preparation Example 1 and Comparative Preparation Examples 1 to 3 were evaluated. Specifically, a 300g portion was tableted and randomly sampled to evaluate the physical properties.
2.1. 안식각 측정2.1. Angle of repose measurement
USP 1174의 Powder flow 챕터에 기재된 분말 안식각 측정방법에 따라 시험하였다. 안식각은 측정각이 작을수록 분체의 유동성이 크다는 것을 의미한다.The test was conducted according to the powder angle of repose measurement method described in the Powder flow chapter of USP 1174. The angle of repose means that the smaller the measured angle, the greater the fluidity of the powder.
2.2. 중량 편차2.2. weight deviation
타정이 완료된 구강붕해정 10개의 검체를 임의로 채취하여 중량편차(%)를 시험하였다.Samples of 10 orally disintegrating tablets after tableting were randomly collected were tested for weight deviation (%).
2.3. 경도 측정2.3. Hardness measurement
구강붕해정의 경도는 경도계(Hardness tester TBH325 TD, Erweka, 독일)를 사용하여 6개의 검체를 측정하여 평균치를 기재하였다.The hardness of the orally dispersible tablets was measured on six samples using a hardness tester TBH325 TD, Erweka, Germany, and the average value was recorded.
2.4. 마손도 측정2.4. Friability measurement
USP 1216의 Tablet friability 챕터에 기재된 정제 마손도 측정방법에 따라 시험하였다.The tablet friability measurement method described in the Tablet friability chapter of USP 1216 was tested.
2.5. 수분흡수율 측정2.5. Water absorption rate measurement
일정 농도의 치자청색소를 포함하는 용액 일정량을 구강붕해정에 점적한 뒤 수분측정기를 사용하여 구강붕해정의 수분 흡수율을 측정하였다. 그 후 측정 완료된 구강붕해정의 단면을 확인하여 정제 내부까지 수분이 흡수되는 정도를 육안평가하였다.A certain amount of a solution containing a certain concentration of gardenia blue pigment was instilled into an orally dispersible tablet, and then the water absorption rate of the orally disintegratable tablet was measured using a moisture meter. Afterwards, the cross-section of the orally dispersible tablet that had been measured was checked and the degree to which moisture was absorbed into the tablet's interior was visually evaluated.
상기 실험예 1 및 실험예 2의 결과를 표 2 및 도 2에 나타내었다.The results of Experimental Examples 1 and 2 are shown in Table 2 and Figure 2.
(°)angle of repose
(°)
(%)weight deviation
(%)
(kp)Hardness
(kp)
(%)Masondo
(%)
표 2 및 도 2에 나타낸 바와 같이, 제조예 1과 같이 과립화 구강붕해제를 사용한 경우에 붕해성이 우수하고 구강붕해정에 적합한 물성을 갖는 것을 알 수 있었다.As shown in Table 2 and Figure 2, when the granulated orally disintegrant was used as in Preparation Example 1, it was found to have excellent disintegration properties and physical properties suitable for orally disintegrating tablets.
구체적으로, 용해시간에 있어서 과립화 구강붕해제를 사용한 제조예 1의 경우 31초로 가장 빠른 용해시간을 나타내어 붕해성이 우수한 것을 알 수 있었다. 안식각에 있어서 제조예 1에서 22.62°로 나타나 비교제조예 1과 비교하여 더 작은 것으로 나타나 유동성이 더 우수한 것을 알 수 있었다. 중량편차의 경우 제조예 1에 있어서 중량편차가 가장 적게 나타나 균일하게 정제를 제조할 수 있음을 알 수 있었다.Specifically, in terms of dissolution time, Preparation Example 1 using a granulated orally disintegrant showed the fastest dissolution time at 31 seconds, showing excellent disintegrability. The angle of repose was found to be 22.62° in Preparation Example 1, which was smaller than that in Comparative Preparation Example 1, indicating better fluidity. In the case of weight deviation, it was found that in Preparation Example 1, the weight deviation was the least and tablets could be manufactured uniformly.
경도가 1미만인 경우에는 정제가 쉽게 부서질 수 있으며, 9초과인 경우에는 정제의 붕해가 지연될 수 있다. 제조예 1의 경우에는 경도가 4.15kp로 나타나 경도가 구강 붕해용 정제에 사용하기에 적합한 수치를 나타냈다. 제조예 1에 있어서 마손도의 수치가 0.39%로 가장 낮게 나타나 가장 우수한 기계적 안정성을 갖는 것을 알 수 있었다.If the hardness is less than 1, the tablet may break easily, and if the hardness is more than 9, disintegration of the tablet may be delayed. In the case of Preparation Example 1, the hardness was 4.15 kp, indicating a value suitable for use in orally disintegrating tablets. In Preparation Example 1, the friability value was the lowest at 0.39%, indicating that it had the best mechanical stability.
수분흡수율을 평가한 결과에서 제조예 1의 경우 24.52%로 나타나 가장 높은 수치를 나타내어 구강 붕해용 정제에 사용하기에 적합한 것을 알 수 있었다.As a result of evaluating the moisture absorption rate, Preparation Example 1 showed the highest value of 24.52%, showing that it is suitable for use in orally disintegrating tablets.
상기의 결과로부터, 과립화 구강붕해제를 사용함으로 인해서 붕해성이 우수하고 구강붕해정에 적합한 물성을 갖는 구강붕해정을 제조할 수 있음을 알 수 있었다.From the above results, it was found that by using a granulated orally disintegrating agent, it was possible to manufacture orally disintegrating tablets with excellent disintegration properties and physical properties suitable for orally disintegrating tablets.
Claims (16)
상기 구강붕해제는 과립화된 것인 구강 붕해 제제. According to paragraph 1,
The orally disintegrating agent is an orally disintegrating preparation that is granulated.
상기 구강붕해제는 구강 붕해 제제 총 중량을 기준으로 1 내지 95 중량%로 포함되는 것인 구강 붕해 제제.According to paragraph 1,
The orally disintegrating agent is an orally disintegrating formulation that is contained in an amount of 1 to 95% by weight based on the total weight of the orally disintegrating formulation.
상기 구강붕해제는 부형제 및 붕해제를 포함하는 것인 구강 붕해 제제.According to paragraph 1,
The orally disintegrating agent is an orally disintegrating formulation containing an excipient and a disintegrant.
상기 부형제는 만니톨, 솔비톨, 자일리톨, 이소말트, 글루코스, 말토덱스트린, 트레할로스, 덱스트로스, 수크로스, 프럭토스, 말토스, 말티톨, 메틸셀룰로오스, 미결정 셀룰로오즈, 유당, 저치환도 히드록시셀룰로오스, 카르복시메칠셀룰로오스 또는 카르복시메칠셀룰오스의 알칼리 금속염, 카라기난, 갈락토만난, 트라가칸트, 펙틴, 키토산 또는 키틴의 유도체, 아라비아고무, 잔탄검, 알긴산 또는 알간산 알칼리 금속, 폴리메타크릴산 또는 그의 염, 메타크릴레이트 공중합체, 폴리비닐알코올, 폴리비닐피롤리돈, 폴리비닐피롤리돈과 비닐아세테이트의 공중합체, 폴리프로필렌옥사이드 및 그의 중합체로 이루어진 군으로부터 선택된 1종 이상인 것인 구강 붕해 제제.According to clause 4,
The excipients include mannitol, sorbitol, xylitol, isomalt, glucose, maltodextrin, trehalose, dextrose, sucrose, fructose, maltose, maltitol, methylcellulose, microcrystalline cellulose, lactose, low-substituted hydroxycellulose, and carboxymethyl. Cellulose or alkali metal salts of carboxymethylcellulose, carrageenan, galactomannan, tragacanth, pectin, chitosan or chitin derivatives, gum arabic, xanthan gum, alginic acid or alkaline metal alganic acid, polymethacrylic acid or its salt, meta An orally disintegrating preparation comprising at least one selected from the group consisting of acrylate copolymer, polyvinyl alcohol, polyvinylpyrrolidone, copolymer of polyvinylpyrrolidone and vinyl acetate, polypropylene oxide, and polymers thereof.
상기 부형제는 만니톨이고, 상기 만니톨의 평균 입자 크기는 10 내지 200 μm 인 것인 구강 붕해 제제.According to clause 4,
The excipient is mannitol, and the average particle size of the mannitol is 10 to 200 μm.
상기 부형제는 구강 붕해 제제 총 중량을 기준으로 1 내지 80 중량%로 포함되는 것인 구강 붕해 제제.According to paragraph 4,
The excipient is an orally disintegrating formulation that is contained in an amount of 1 to 80% by weight based on the total weight of the orally disintegrating formulation.
상기 붕해제는 옥수수전분, 히드록시프로필메칠셀룰로오스, 벤토나이트, 히드록시프로필스타치, 카르복시메칠셀룰로오스나트륨, 알긴산나트륨, 라우릴황산나트륨, 무수규산, 1-히드록시프로필셀룰로오스, 덱스트란, 이온교환수지, 초산폴리비닐, 포름알데히드처리 카제인 및 젤라틴, 알긴산, 아밀로오스, 구아르고무(Guar gum), 중조 폴리비닐피롤리돈, 아라비아고무, 아밀로펙틴, 펙틴, 폴리인산나트륨, 에칠셀룰로오스, 백당 및 규산마그네슘알루미늄으로 이루어진 군으로부터 선택된 1종 이상인 것인 구강 붕해 제제.According to paragraph 4,
The disintegrant includes corn starch, hydroxypropyl methyl cellulose, bentonite, hydroxypropyl starch, sodium carboxymethyl cellulose, sodium alginate, sodium lauryl sulfate, silicic anhydride, 1-hydroxypropyl cellulose, dextran, ion exchange resin, Made of polyvinyl acetate, formaldehyde-treated casein and gelatin, alginic acid, amylose, guar gum, polyvinylpyrrolidone sodium bicarbonate, gum arabic, amylopectin, pectin, sodium polyphosphate, ethyl cellulose, sucrose, and magnesium aluminum silicate. An orally disintegrating preparation comprising at least one selected from the group consisting of:
상기 붕해제는 옥수수전분이고, 상기 옥수수전분의 평균 입자 크기는 10 내지 200 μm인 것인 구강 붕해 제제.According to paragraph 4,
The disintegrant is corn starch, and the average particle size of the corn starch is 10 to 200 μm.
상기 붕해제는 구강 붕해 제제 총 중량을 기준으로 1 내지 20 중량%로 포함되는 것인 구강 붕해 제제.According to paragraph 4,
The disintegrant is an orally disintegrating formulation containing 1 to 20% by weight based on the total weight of the orally disintegrating formulation.
감미료, 산미료, 향료, 색소류, 항산화제, 안정화제, 계면활성제로 이루어진 군으로부터 선택된 1종 이상의 첨가제를 포함하는 것인 구강 붕해 제제.According to paragraph 1,
An orally disintegrating preparation containing one or more additives selected from the group consisting of sweeteners, acidulants, flavorings, colorants, antioxidants, stabilizers, and surfactants.
상기 구강 붕해 제제는 정제(tablet), 필름제, 현탁제(suspension), 과립제(granule), 겔제(gel), 환제(pill), 틴크제(tincture), 전제(decoction), 침제(infusion), 주정제(spirit), 유동엑스제(fluidextract), 엘릭서제(elixir), 엑스제(extract), 시럽제(syrup), 산제(powder), 방향수제(aromatic water) 또는 레모네이드제(lemonade) 제형인 것인 구강 붕해 제제.According to paragraph 1,
The orally disintegrating preparations include tablets, films, suspensions, granules, gels, pills, tinctures, decoctions, infusions, It is in the form of a spirit, fluidextract, elixir, extract, syrup, powder, aromatic water or lemonade. Phosphorus orally disintegrating formulation.
상기 정제는 구강붕해정(orally disintegrating tablet), 부착정(mucoadhesive tablet), 분산정(dispersible tablet), 설하정(sublingual tablet), 바칼정(buccal tablet), 저작정(chewable tablet), 비등정(발포정-effervescent tablet) 또는 용해정(solution tablet) 형태인 것인 구강 붕해 제제.According to clause 12,
The tablets include orally disintegrating tablets, mucoadhesive tablets, dispersible tablets, sublingual tablets, buccal tablets, chewable tablets, and effervescent tablets ( An orally disintegrating preparation in the form of an effervescent tablet or a solution tablet.
상기 루바브뿌리추출물은 구강 붕해 제제 총 중량을 기준으로 0.13334 내지 4 중량%로 포함되는 것인 구강 붕해 제제.According to paragraph 1,
The rhubarb root extract is an orally disintegrating preparation comprising 0.13334 to 4% by weight based on the total weight of the orally disintegrating preparation.
붕해시간이 180초 이내, 경도 1 내지 9kp, 마손도 0.01 내지 0.8%인 것인 구강 붕해 제제.According to paragraph 1,
An orally disintegrating preparation having a disintegration time of less than 180 seconds, hardness of 1 to 9 kp, and friability of 0.01 to 0.8%.
ii) 상기 구강붕해제 및 루바브뿌리추출물을 혼합하는 단계; 및
iii) 상기 혼합물을 제제화 하는 단계를 포함하는 루바브뿌리추출물 및 구강붕해제를 포함하는 구강 붕해 제제의 제조 방법.i) mixing excipients and disintegrants and granulating to prepare an orally disintegrant;
ii) mixing the orally disintegrant and rhubarb root extract; and
iii) A method for producing an orally disintegrating formulation containing a rhubarb root extract and an orally disintegrant, including the step of formulating the mixture.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020220078664 | 2022-06-28 | ||
KR20220078664 | 2022-06-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20240002123A true KR20240002123A (en) | 2024-01-04 |
Family
ID=89542679
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020220131344A KR20240002123A (en) | 2022-06-28 | 2022-10-13 | Oral disintegrating formulation containing rhubarb root extract and manufacturing method thereof |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR20240002123A (en) |
-
2022
- 2022-10-13 KR KR1020220131344A patent/KR20240002123A/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6187336B1 (en) | Process for producing a solid which is rapidly soluble in the oral cavity | |
ES2239783T3 (en) | MATERIALS MOLDED BY COMPRESSION, FAST DISINTEGRATION, AND ITS PRODUCTION PROCEDURE. | |
RU2493831C2 (en) | Pharmaceutical compositions | |
WO1999018936A1 (en) | Quickly soluble solid preparations | |
TWI376243B (en) | Oral disintegrating tablet | |
US20110014132A1 (en) | Solid effervescent mixture for the oral absorption | |
JP2010540588A (en) | Orally disintegrating tablets | |
JP5342028B2 (en) | Orally disintegrating tablets | |
EP2050448A1 (en) | Oral disintegrating tablet having masked bitter taste and method for production thereof | |
KR101203186B1 (en) | Taste-masked pharmaceutical composition for oral administration and a process for the preparation thereof | |
MX2014004811A (en) | Taste-masked pharmaceutical composition for oral administration and a process for the preparation thereof. | |
CN100546571C (en) | Sangju effervescent tablet for treating common cold | |
CN105381019A (en) | Effervescent tablet with internal-fire clearing function and preparation method thereof | |
CN111065384A (en) | Composition of orally disintegrating film of paracetamol | |
CN102100902B (en) | Counterflow effervescent tablets | |
CN101543298B (en) | Rutin chewing agent and method for preparing same | |
KR20240002123A (en) | Oral disintegrating formulation containing rhubarb root extract and manufacturing method thereof | |
WO2005072717A1 (en) | Biguanide preparation for internal use | |
CN103781371A (en) | Solid composition | |
CN102525978A (en) | Children amoxicillin-potassium clavulanate composition | |
CN100450470C (en) | Rapid disintegrate tablet in oral and its preparation method | |
KR101352689B1 (en) | Microgranule preparations comprising agglumerate units consisting of discontinuous phase and continuous phase | |
CN102247331B (en) | Cefadroxil chewable tablets and preparation method thereof | |
KR20210147707A (en) | Composition for relieving and preventing hangover comprising Oenanthe javanica extracts | |
KR101621502B1 (en) | A preparation method of an effervescent preparation comprising an extract of saengmacksan prescription |